Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

Sanofi S.A. Part Cert-1.97% €8.03M ...